Diabetes:纵向结果支持糖化血红蛋白6.5的诊断阈值

2012-08-21 高晓方 医学论坛网

  美日学者的一项研究表明,纵向研究结果支持糖化血红蛋白(HbA1c)阈值≥6.5%诊断糖尿病的有效性。论文于2012年8月13日在线发表于《糖尿病》(Diabetes)杂志。    HbA1c阈值基于横断面研究证据而制定,尚无纵向研究支持其有效性。此项研究共纳入19897例日本成人受试者,并对其进行了为期3年的随访。利用Logistic回归模型和限制性立方样条模型评估基线HbA1c水平与视网膜

  美日学者的一项研究表明,纵向研究结果支持糖化血红蛋白(HbA1c)阈值≥6.5%诊断糖尿病的有效性。论文于2012年8月13日在线发表于《糖尿病》(Diabetes)杂志。

   HbA1c阈值基于横断面研究证据而制定,尚无纵向研究支持其有效性。此项研究共纳入19897例日本成人受试者,并对其进行了为期3年的随访。利用Logistic回归模型和限制性立方样条模型评估基线HbA1c水平与视网膜病变患病率与3年发病率的相关性。

  结果显示,限制性立方样条模型提示偶发性视网膜病变风险的可能阈值为HbA1c 6.0%~7.0%。Logistic回归分析显示,与HbA1c 5.0%~5.4%相比,HbA1c 6.5%~6.9%的受试者罹患视网膜病变的风险显著升高。HbA1c 5.5%~6.4%的受试者无风险升高证据。

  链接:Yusuke Tsugawa1, Osamu Takahashi2, James B. Meigs3, Roger B. Davis1,4, Fumiaki Imamura5,Tsuguya Fukui2, William C. Taylor1 and Christina C. Wee1  New Diabetes Diagnostic Threshold of Hemoglobin A1c and the 3-Year Incidence of Retinopathy.Diabetes

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1759180, encodeId=406a1e59180c3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Jan 12 03:32:00 CST 2013, time=2013-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636549, encodeId=0d3f1636549c2, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Apr 02 15:32:00 CST 2013, time=2013-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900989, encodeId=98e2190098969, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jul 22 03:32:00 CST 2013, time=2013-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553580, encodeId=79eb1553580f2, content=<a href='/topic/show?id=839e9e33475' target=_blank style='color:#2F92EE;'>#阈值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97334, encryptionId=839e9e33475, topicName=阈值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f4f14387940, createdName=qjddjq, createdTime=Thu Aug 23 01:32:00 CST 2012, time=2012-08-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1759180, encodeId=406a1e59180c3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Jan 12 03:32:00 CST 2013, time=2013-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636549, encodeId=0d3f1636549c2, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Apr 02 15:32:00 CST 2013, time=2013-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900989, encodeId=98e2190098969, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jul 22 03:32:00 CST 2013, time=2013-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553580, encodeId=79eb1553580f2, content=<a href='/topic/show?id=839e9e33475' target=_blank style='color:#2F92EE;'>#阈值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97334, encryptionId=839e9e33475, topicName=阈值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f4f14387940, createdName=qjddjq, createdTime=Thu Aug 23 01:32:00 CST 2012, time=2012-08-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1759180, encodeId=406a1e59180c3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Jan 12 03:32:00 CST 2013, time=2013-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636549, encodeId=0d3f1636549c2, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Apr 02 15:32:00 CST 2013, time=2013-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900989, encodeId=98e2190098969, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jul 22 03:32:00 CST 2013, time=2013-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553580, encodeId=79eb1553580f2, content=<a href='/topic/show?id=839e9e33475' target=_blank style='color:#2F92EE;'>#阈值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97334, encryptionId=839e9e33475, topicName=阈值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f4f14387940, createdName=qjddjq, createdTime=Thu Aug 23 01:32:00 CST 2012, time=2012-08-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1759180, encodeId=406a1e59180c3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Jan 12 03:32:00 CST 2013, time=2013-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636549, encodeId=0d3f1636549c2, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Apr 02 15:32:00 CST 2013, time=2013-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900989, encodeId=98e2190098969, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jul 22 03:32:00 CST 2013, time=2013-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553580, encodeId=79eb1553580f2, content=<a href='/topic/show?id=839e9e33475' target=_blank style='color:#2F92EE;'>#阈值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97334, encryptionId=839e9e33475, topicName=阈值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f4f14387940, createdName=qjddjq, createdTime=Thu Aug 23 01:32:00 CST 2012, time=2012-08-23, status=1, ipAttribution=)]
    2012-08-23 qjddjq

相关资讯

Arch Intern Med :强化降糖对肾脏终点事件预防效果不佳

    美国一项荟萃分析显示,与常规血糖控制相比,强化血糖控制对2型糖尿病患者的肾脏预后无显著影响。论文5月28日发表于《内科学文献》(Arch Intern Med 2012,172(10):761)杂志。       研究者通过对1950年1月1日至2010年12月31日间的文献进行检索,确定了7项比较2型糖尿病患者接受强化血糖控制与接受常

2型糖尿病致老年骨形成降低

  近日,苏州大学附属第二医院内分泌代谢病科的庞东岳、史蕾、张弘弘等共同发表论文,旨在通过测定男性2型糖尿病(T2DM)患者及健康人群的骨代谢及相关指标,探讨T2DM对骨代谢的影响及其相关因素。研究指出,与正常对照组相比,T2DM患者的骨形成降低,而骨吸收增加。随着病程增加,T2DM患者骨质形成速率进一步减慢,而骨吸收无明显增加。血糖控制不佳可致骨形成减缓、骨质吸收增加而影响骨代谢。该论文发表于2

Diabetes Care:糖化血红蛋白低水平或预测普通人群死亡

  美国学者的一项研究表明,在普通人群中,糖化血红蛋白(HbA1c)低水平可能为死亡风险的泛化标志物。论文于2012年7月30日在线发表于《糖尿病护理》(Diabetes Care)杂志。    此项前瞻性队列研究共纳入13288例受试者。利用Logistic回归分析确认低HbA1c(<5%)的横断面相关性,并利用Cox比例风险模型评估低HbA1c与死因别死亡率的相关性。   结果显示,

HbA1c不可靠时可改测糖化白蛋白(果糖胺)

      美国杜克大学的Thomas L. O' Connell博士在美国医师协会(ACP)年会上指出,如果遇到糖化血红蛋白A1c(HbA1c)与血糖监测数据不一致的情况,应当提高警惕。   Connell博士强调,由于任何可影响血红蛋白的因素都会干扰HbA1c检查,因此HbA1c与血糖监测结果不一致的情况实际上相当常见。例如,正在接受血液透析、近期接受了输血、患

争鸣:HbA1c目标值需个体化?

  糖化血红蛋白(HbA1c)能反映患者近8~12周血糖平均水平,是评价血糖控制水平的公认指标,但其个体化的目标值尚存争议。《中国成人2型糖尿病(T2DM)HbA1c 控制目标的专家共识》(2010版,简称共识)提出:可根据病情每3~6个月进行1次HbA1c监测;不笼统推荐成人T2DM的HbA1c控制目标值,应根据病情分层和社会因素差异建议相对合理的HbA1c值,力争做到安全达标,《共识》中目标值